APO-HYDROMORPHONE 2 MG
HYDROMORPHONE HYDROCHLORIDE : 2 MG · DIN 02364123 · APOTEX INC
Health Canada status: MARKETED
What is APO-HYDROMORPHONE?
APO-HYDROMORPHONE 2 MG contains HYDROMORPHONE HYDROCHLORIDE : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02364123, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Dec-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-HYDROMORPHONE used for?
Relief of moderate to severe pain in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02364123 |
|---|---|
| Brand name | APO-HYDROMORPHONE |
| Generic / active ingredient | HYDROMORPHONE HYDROCHLORIDE : 2 MG |
| Manufacturer | APOTEX INC |
| Strength | 2 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA03 HYDROMORPHONE |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Dec-2012 |
| Original market date | 2012-12-18 00:00:00 |
How is it administered?
Adults: 2 to 4 mg every 4 to 6 hours as required. Tablets must be swallowed whole. Dosing should be individualized and titrated to the lowest effective dose. Max 18 mg/day for chronic non-cancer pain.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store securely to avoid theft or misuse. (Specific temperature range not provided in text, but standard practice is 15-30°C).
How is it supplied?
Bottles of 100 tablets and blister packages of 4 x 25 tablets.
Contraindications
Hypersensitivity to hydromorphone or opioids; GI obstruction; suspected surgical abdomen; mild pain; asthma/COPD; respiratory depression; acute alcoholism; severe CNS depression; head injury; MAOIs.
Warnings and precautions
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; fatal overdose risk if crushed/chewed; neonatal opioid withdrawal syndrome; risks with alcohol/benzodiazepines.
Is HYDROMORPHONE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by STERIMAX INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02AA03 HYDROMORPHONE. 34 of 85 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-HYDROMORPHONE | 1 MG | TABLET | APOTEX INC | MARKETED | DIN 02364115 |
| APO-HYDROMORPHONE | 4 MG | TABLET | APOTEX INC | MARKETED | DIN 02364131 |
| APO-HYDROMORPHONE | 8 MG | TABLET | APOTEX INC | MARKETED | DIN 02364158 |
| DILAUDID | 1 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00705438 |
| DILAUDID | 2 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00125083 |
| DILAUDID | 4 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00125121 |
| DILAUDID | 8 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00786543 |
| HYDROMORPH CONTIN | 4.5 MG | CAPSULE (SUSTAINED-RELEASE) | PURDUE PHARMA | MARKETED | DIN 02359502 |
| HYDROMORPH CONTIN | 9 MG | CAPSULE (SUSTAINED-RELEASE) | PURDUE PHARMA | MARKETED | DIN 02359510 |
| HYDROMORPH CONTIN-CONTROLLED RELEASE CAP - 12MG | 12 MG | CAPSULE (SUSTAINED-RELEASE) | PURDUE PHARMA | MARKETED | DIN 02125366 |
Who else supplies HYDROMORPHONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HYDROMORPHONE appears in 134 registered pack listings across 6 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.